GlassScriptPhysician profile
Eva Hausnerova
NPI 1639106172
$4,446.36
in general payments reported to CMS, 2019-2025
33 companies · $899 in 2025
The $899 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $836 · 2020: $536 · 2021: $571 · 2022: $386 · 2023: $723 · 2024: $496 · 2025: $899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $745.86 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.30 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $499.32 | 2019-2025 | |
| Pfizer INC. | $374.72 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $326.61 | 2020-2023 | Xarelto |
| Amgen INC. | $180.99 | 2019-2025 | Repatha |
| Merck Sharp & Dohme LLC | $172.94 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $172.51 | 2019-2021 | |
| Bridgebio Pharma, INC. | $152.51 | 2025 | Attruby |
| Abbott Laboratories | $130.15 | 2020 | |
| Chiesi USA, INC. | $130.13 | 2019 | |
| Boston Scientific Corporation | $119.10 | 2019 | |
| Alnylam Pharmaceuticals INC. | $102.41 | 2025 | Amvuttra |
| Genzyme Corporation | $101.65 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $76.41 | 2023 | Opsumit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.73 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $61.55 | 2019-2021 | |
| Atricure, INC. | $60.96 | 2022 | |
| Esperion Therapeutics, INC. | $54.52 | 2021-2025 | Nexletol |
| Baxter Healthcare | $44.95 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Scpharmaceuticals INC. | $34.90 | 2023 | |
| Corcept Therapeutics | $23.75 | 2021 | |
| Medtronic, INC. | $23.53 | 2021 | |
| Inspire Medical Systems, INC. | $23.30 | 2025 | Inspire |
| Glaxosmithkline, LLC. | $22.84 | 2025 | |
| Astellas Pharma US INC | $20.71 | 2021 | |
| Daiichi Sankyo INC. | $20.67 | 2021 | |
| Lilly USA, LLC | $18.98 | 2025 | Zepbound |
| Philips North America LLC | $18.44 | 2024 | (Ck7) Extended Holter |
| Azurity Pharmaceuticals, INC. | $15.23 | 2023 | Edarbi |
| Endo Pharmaceuticals INC. | $15.17 | 2020 | |
| Cmp Pharma, INC. | $14.58 | 2023 | Carospir, Tadliq, Norliqva |
| Irhythm Technologies, INC. | $13.94 | 2024 | Zio Xt Patch, Zio Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Hausnerova listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.